Data supports accuracy and performance of Nucleix’s Bladder Epicheck in NMIBC surveillance

An independent analysis of studies of Nucleix Ltd.’s Bladder Epicheck demonstrate high diagnostic accuracy and performance in monitoring for disease recurrence in patients with non-muscle invasive bladder cancer (NMIBC).